1. Dyck PJ, Albers JW, Andersen H et al. Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 2011.
2. Tesfaye S, Boulton AJ, Dyck PJ et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33 (10): 2285–93.
3. Brown MJ, Asbury AK. Diabetic neuropathy. Ann Neurol 1984; 15: 2–12.
4. Zochodne DW. Diabetic neuropathies: features and mechanisms. Brain Pathol 1999; 9: 369–91.
5. Boulton AJM, Vinik AI, Arezzo JC et al. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 2005; 28: 956–62.
6. Abbott CA, Malik RA, Van Ross ERE et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011; 34: 2220–4.
7. Ziegler D, Hanefeld M, Ruhnau KJ et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant a-lipoic acid. A 3-week multicentre randomized controlled trial (ALA-DIN Study). Diabetologia 1995; 38: 1425–33.
8. Reljanovic M, Reichel G, Rett K et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999; 31 (3): 171–9.
9. Ziegler D, Hanefeld M, Ruhnau RJ et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999; 22 (8): 1296–301.
10. Ametov A, Barinov A, O'brien P et al, the SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY Trial. Diabetes Care 2003; 26: 770–6.